BioMarin’s $475M Fabry Disease Licensing Deal | Lucid Diligence Brief
This Lucid Diligence Brief explores BioMarin’s expansion of its Fabry disease…
Rare Diseases Today—May 21, 2026
This week’s Rare Diseases update highlights regulatory progress, orphan…
Cell and Gene Therapy Today—February 26, 2026
This week's Cell and Gene therapy update highlights regulatory momentum,…
Cell and Gene Therapy Clinical Trials – 2024 Edition
Gene therapy clinical trials promise transformative breakthroughs in treating…



